

PATROL

higher-risk chronic myelomonocytic leukemia (CMML)

Contatti: P.I. Elena Crisà elena.crisa@ircc.it

Linea terapeutica: I linea

Terapia: azacitidine (AZA) combined with venetoclax (VEN) and tagraxofusp (TAG)

Coorti: Single ARM Phase 2

Inclusion:

- CPSS risk intermediate-2 or high at study entry
- No prior HMA or VEN treatment (acceptable prior treatment with ESA or HY, with a >15 and > 3 days washout, respectively)
- ECOG PS 0-2

Exclusion:

previously received HSCT